ABLYNX ANNOUNCES WARRANT EXERCISE
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 21 October 2013 - Ablynx [Euronext Brussels: ABLX] today
announced, in conformity with Title II of the Law of 2 May 2007 and the Royal
Decree of 14 February 2008, that an additional 25,531 common shares have been
issued by the Company in exchange for 147,161.69 Euro as the result of the
exercise of warrants by some employees and consultants of the Company.
As a result of this transaction, Ablynx now has 48,827,646 shares outstanding.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
pdf version of the press release:
http://hugin.info/137912/R/1737065/582289.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1737065]
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2013 - 18:00 Uhr
Sprache: Deutsch
News-ID 307719
Anzahl Zeichen: 2727
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 127 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES WARRANT EXERCISE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
